{ "schemaVersion": 2, "eyebrow": "Reproductive Psychiatry", "title": "Premenstrual Dysphoric Disorder", "summary": "Confirm PMDD with prospective daily ratings before attributing cyclic symptoms to a primary mood disorder. Distinguish PMDD from premenstrual exacerbation, assess suicidality urgently, and select SSRIs, ovulation suppression, or CBT according to symptom pattern, contraceptive needs, comorbidity, and treatment response.", "seoDescription": "A physician-focused guide to confirming PMDD, distinguishing premenstrual exacerbation, assessing safety, and selecting evidence-based treatment.", "clinicalQuestion": "How should clinicians confirm PMDD, exclude premenstrual exacerbation and alternative causes, and choose initial versus refractory treatment?", "specialty": "Obstetrics and Gynecology", "audience": "U.S. physicians and medical trainees", "tags": [ "PMDD", "premenstrual dysphoric disorder", "DRSP", "premenstrual exacerbation", "SSRIs", "drospirenone", "menstrual-cycle mood disorders" ], "keyTakeaways": [ "Do not diagnose PMDD from retrospective history alone; use daily prospective symptom ratings for at least 2 symptomatic cycles, with the DRSP as a validated practical instrument. [12][14][17]", "PMDD requires at least 5 symptoms, including at least 1 core affective symptom, occurring premenstrually, improving soon after menses begins, and becoming minimal or absent after menses; clinically significant impairment is required. [16][18]", "A persistent disorder with premenstrual worsening is premenstrual exacerbation (PME), not PMDD alone; assess baseline symptoms and treat the underlying mood, anxiety, or personality disorder concurrently. [14][16]", "Assess suicidal ideation and acute psychiatric distress at presentation; these warrant urgent mental-health evaluation rather than waiting for prospective charting. [17]", "SSRIs are first-line pharmacotherapy; continuous and luteal-phase regimens are both supported, although a recent Cochrane review found continuous dosing may be more effective. [5][19]", "For patients desiring hormonal contraception, drospirenone-containing combined oral contraception is a therapeutic option; hormonal mood effects are heterogeneous, so reassess mood after initiation. [2][3]" ], "sections": [ { "id": "safety-and-provisional-assessment", "eyebrow": "First Visit", "heading": "Address acute risk while establishing a provisional diagnosis", "intro": "Do not delay safety assessment while awaiting two-cycle symptom confirmation.", "paragraphs": [ "At the initial visit, directly assess suicidal ideation, intent, plan, prior attempts, psychosis, mania or hypomania, substance use, and inability to maintain safety. Suicidal ideation or significant psychiatric distress requires prompt mental-health evaluation and safety intervention; prospective charting is used to confirm cyclicity, not to defer acute care. [17]", "A retrospective history can justify a provisional PMDD diagnosis and initial symptom-directed treatment, but it does not establish the diagnosis. Ask the patient to identify the first day of bleeding, symptom-free days, use of hormonal contraception, and whether clinically important depression, anxiety, irritability, or interpersonal dysfunction persists outside the luteal phase. Prospective daily ratings across at least 2 consecutive symptomatic cycles must confirm the diagnosis. [14][16][18]", "Review drugs and exposures that can produce mood symptoms, and assess medical alternatives when indicated by history or examination. DSM-based criteria require that symptoms not be attributable to a substance, medication, other treatment, or medical disorder; hyperthyroidism is a named alternative medical explanation. [14][18]" ], "bullets": [ "Document cycle timing, bleeding pattern, pregnancy possibility, hormonal regimen, and psychiatric treatment before interpreting diary data. [16][17]", "If bipolar-spectrum illness is suspected from a history of mania or hypomania, avoid treating the presentation as isolated PMDD without psychiatric assessment; bipolar disorder is a frequent diagnostic overlap. [4]", "Use the prospective diary interval to establish a safety plan, initiate indicated treatment, and arrange follow-up rather than offering reassurance alone. [17]" ], "subsections": [], "table": { "caption": "Initial triage priorities for suspected PMDD. [17]", "columns": [ "Finding", "Interpretation", "Immediate action" ], "rows": [ [ "Suicidal ideation, plan, intent, or inability to maintain safety", "Acute psychiatric risk may coexist with a menstrual-cycle disorder. [17]", "Perform urgent safety assessment and obtain prompt mental-health evaluation. [17]" ], [ "Mania, hypomania, psychosis, or major noncyclic mood symptoms", "Consider bipolar-spectrum or another primary psychiatric disorder rather than isolated PMDD. [4][16]", "Obtain psychiatric assessment and chart daily symptoms across the cycle. [14][16]" ], [ "Clear luteal symptoms but no prospective documentation", "PMDD may be diagnosed provisionally only. [14][16][18]", "Begin daily DRSP ratings for at least 2 symptomatic cycles. [12][17]" ] ] } }, { "id": "confirming-pmdd", "eyebrow": "Diagnostic Standard", "heading": "Confirm the cyclic pattern with daily DRSP ratings", "intro": "The diagnostic discriminator is a symptom-free or near-symptom-free postmenstrual interval.", "paragraphs": [ "Use the Daily Record of Severity of Problems (DRSP) each day for at least 2 consecutive symptomatic cycles. The DRSP includes 24 items: 21 items spanning 11 symptom domains and 3 items addressing functional impairment; each item is rated from 1, not at all, to 6, extreme. This prospective record is more reliable than retrospective symptom recall and establishes timing, severity, and functional consequences. [15][17]", "Confirm DSM-pattern timing: symptoms occur in the final week before menses, improve within a few days after menstrual bleeding begins, and become minimal or absent in the week after menses. Symptoms must be present in most menstrual cycles over the preceding year, although prospective two-cycle documentation is the required confirmation step. [16][18]", "Require at least 5 of 11 symptoms, including at least 1 core affective symptom: affective lability, irritability or anger, depressed mood or hopelessness, or anxiety or tension. Additional qualifying symptoms include diminished interest, concentration difficulty, low energy, appetite change, sleep disturbance, feeling overwhelmed or out of control, and physical symptoms. The symptoms must cause clinically significant distress or impairment in work, school, social activities, or relationships. [16][18]" ], "bullets": [ "Record functional impairment separately; symptom count without clinically significant impairment does not establish PMDD. [14][16]", "Use C-PASS when available to standardize interpretation of daily ratings across symptom content, severity, cyclicity, and chronicity. [14][15]", "C-PASS operationalizes a qualifying symptom as at least moderate severity, a rating of 4 on its 1-to-6 scale, for at least 2 days in the premenstrual week. [15]" ], "subsections": [], "table": { "caption": "PMDD diagnostic elements to apply to prospective daily ratings. [14][16][18]", "columns": [ "Element", "Required finding", "Clinical implication" ], "rows": [ [ "Timing", "Symptoms peak in the final premenstrual week, improve within days after bleeding begins, and are minimal or absent the following week. [16][18]", "A continuous symptom burden argues against isolated PMDD. [14][16]" ], [ "Symptom burden", "At least 5 of 11 symptoms, including at least 1 core affective symptom. [16][18]", "Fewer qualifying symptoms may represent another menstrual-related disorder rather than PMDD. [15]" ], [ "Severity", "Clinically significant distress or functional impairment. [14][16]", "Treat impairment as a diagnostic criterion, not an optional severity descriptor. [14]" ], [ "Prospective confirmation", "Daily ratings for at least 2 symptomatic cycles. [12][14][16]", "A provisional diagnosis may precede confirmation. [14][16][18]" ] ] } }, { "id": "distinguishing-pmdd-from-pme", "eyebrow": "Differential", "heading": "Distinguish PMDD from premenstrual exacerbation", "intro": "The key branch point is whether symptoms remit outside the luteal phase.", "paragraphs": [ "Premenstrual exacerbation is worsening of an existing psychiatric disorder before menses, whereas PMDD requires a distinct cyclical pattern with symptoms minimal or absent after menses. Major depressive disorder, persistent depressive disorder, panic disorder, anxiety disorders, and personality disorders can coexist with PMDD but cannot be relabeled PMDD if the diary shows substantial symptoms throughout the cycle. [14][16]", "Use daily ratings to compare premenstrual symptom burden with the postmenstrual week rather than relying on a report that symptoms are “worse before the period.” In research applying C-PASS, clinically significant PME was operationalized as at least a 30% premenstrual increase relative to the postmenstrual week for an emotional symptom; this quantifies worsening but does not substitute for the full PMDD diagnostic pattern. [13]", "In patients with borderline personality disorder, daily DRSP data may reveal meaningful premenstrual elevations in depression, anxiety, anger, rejection sensitivity, or interpersonal conflict. This pattern should prompt treatment of the baseline personality disorder and risk assessment in addition to cycle-specific interventions; it should not be assumed to represent PMDD without the required symptom-free interval and full criteria. [13][14][16]" ], "bullets": [ "Screen for current depression, anxiety, panic symptoms, trauma-related symptoms, and bipolar-spectrum history before attributing all mood change to PMDD. [4][14][16]", "If daily ratings demonstrate a persistent baseline disorder plus premenstrual worsening, document PME and optimize treatment of the underlying disorder rather than using intermittent therapy as the sole strategy. [14][16]", "If medication adverse effects, substance exposure, or a medical disorder temporally explains symptoms, do not diagnose PMDD until that alternative explanation is addressed. [14][18]" ], "subsections": [], "table": { "caption": "Diary-based distinction between PMDD and common mimics. [13][14][16][18]", "columns": [ "Pattern", "Daily-rating finding", "Next step" ], "rows": [ [ "PMDD", "At least 5 qualifying symptoms with luteal-phase onset, postmenstrual remission, and impairment. [16][18]", "Initiate PMDD-directed treatment while monitoring diary response. [17][19]" ], [ "Premenstrual exacerbation", "Underlying symptoms remain outside the luteal phase but intensify premenstrually; a 30% premenstrual increase is one C-PASS research threshold for emotional symptoms. [13][14]", "Treat the baseline psychiatric disorder and address cyclic worsening. [14][16]" ], [ "Medication, substance, or medical cause", "Timing is better explained by an exposure, treatment, or condition such as hyperthyroidism. [14][18]", "Evaluate and correct the alternative cause before assigning PMDD. [14][18]" ] ] } }, { "id": "initial-treatment", "eyebrow": "Treatment", "heading": "Choose first-line treatment by symptom pattern and contraceptive goals", "intro": "SSRIs and selected combined oral contraceptives are principal medication options.", "paragraphs": [ "Offer an SSRI as first-line pharmacotherapy when mood symptoms or functional impairment are clinically significant. Fluoxetine, sertraline, and paroxetine are the SSRIs identified as FDA-approved in the United States for severe PMS/PMDD. SSRIs have rapid PMDD symptom effects, reported within 1 to 2 days, permitting either continuous administration or treatment confined to the luteal phase. [10][19]", "Select continuous SSRI dosing when symptoms extend beyond the luteal phase, when PME or another depressive or anxiety disorder is present, or when a patient prefers a consistent regimen. Luteal-phase dosing, typically begun 10 to 14 days before anticipated menses, can reduce medication exposure and adverse effects for patients with a clearly limited premenstrual symptom window. A 2024 Cochrane review of 34 randomized trials concluded that SSRIs reduce PMDD symptoms and that continuous dosing may be more effective than intermittent dosing. [5][19]", "Before prescribing, discuss nausea, insomnia, fatigue, nervousness, headache, and sexual dysfunction. Reassess daily ratings, adverse effects, adherence, functional impairment, and suicidal thinking after treatment initiation; use the same prospective instrument to determine whether the premenstrual symptom peak and impairment have diminished. [17][19]", "For patients who desire contraception and do not have contraindications to combined hormonal contraception, a drospirenone-containing combined oral contraceptive is a reasonable hormonal option. Hormonal effects on mood are not uniform: some individuals improve while others worsen, so establish a baseline diary and reassess after initiation rather than presuming a class-wide psychiatric effect. [2][3]" ], "bullets": [ "Use cognitive-behavioral therapy as a nonpharmacologic treatment option, particularly when the patient prefers psychotherapy, has medication intolerance, or needs coping and behavioral strategies; benefits for premenstrual symptoms have been reported without recorded adverse effects. [1][21]", "Regular exercise, stress reduction, and structured lifestyle interventions can be offered as adjuncts, but they should not replace SSRI treatment or urgent psychiatric intervention in severe, functionally impairing illness. [1][2]", "When initiating a combined oral contraceptive in a patient with substantial mood symptoms, give explicit instructions to report mood deterioration or new suicidal ideation promptly. [3][7]" ], "subsections": [], "table": { "caption": "Treatment selection for confirmed or provisionally diagnosed PMDD. [1][2][3][5][10][19]", "columns": [ "Clinical situation", "Preferred approach", "Key tradeoff or monitoring" ], "rows": [ [ "Predominantly luteal symptoms; no important symptoms outside that interval", "Consider luteal-phase SSRI treatment, started approximately 10 to 14 days before menses. [19]", "May reduce adverse-effect exposure; confirm symptom timing with daily ratings. [17][19]" ], [ "PME, comorbid depression or anxiety, or symptoms beyond the luteal phase", "Prefer continuous SSRI treatment. [5][14][16]", "Continuous dosing may be more effective than intermittent dosing and treats baseline symptoms. [5]" ], [ "Needs effective contraception and seeks hormonal treatment", "Consider a drospirenone-containing combined oral contraceptive. [2][3]", "Mood may improve or worsen; reassess prospectively after initiation. [3]" ], [ "Prefers nonpharmacologic treatment or cannot tolerate medication", "Offer CBT; add exercise and stress-reduction strategies. [1][2][21]", "Monitor functional outcomes and diary scores rather than assuming symptom control. [17]" ] ] } }, { "id": "refractory-pmdd", "eyebrow": "Escalation", "heading": "Reserve ovulation suppression for refractory, confirmed PMDD", "intro": "Escalate only after reconfirming diagnosis, adherence, comorbidity, and treatment target.", "paragraphs": [ "Before labeling PMDD refractory, review the prospective diary for a true postmenstrual remission, determine whether the apparent failure is actually PME or an untreated baseline disorder, and verify the treatment schedule and tolerability. This reassessment matters because diagnostic overlap with depression, anxiety, bipolar disorder, and personality disorders is common. [4][14][16]", "Gonadotropin-releasing hormone agonists suppress ovulation and usually decrease PMDD symptoms; they are a hormonal suppression option for refractory illness rather than routine initial therapy. Their use should follow confirmation of a cycle-linked disorder and a careful discussion of the consequences of abolishing ovarian hormone fluctuations and the safety implications of longer-term hormonal suppression. [2][8][20]", "Refer patients with persistent severe impairment, uncertain bipolar-spectrum illness, suicidal symptoms, complex psychiatric comorbidity, or failure of SSRI and contraceptive-based strategies to clinicians with reproductive psychiatry and gynecology expertise. The referral question should specify whether the diary demonstrates PMDD, PME, or both, because that distinction determines whether continuous psychiatric treatment, hormonal suppression, or combined care is needed. [4][14][16]" ], "bullets": [ "Use the DRSP or another daily instrument longitudinally after every major treatment change to document response and detect persistent noncyclic symptoms. [17]", "Do not use ovulation suppression as a diagnostic shortcut when daily ratings do not show the required timing and remission pattern. [14][16][18]", "Reassess suicidality whenever symptoms intensify, treatment is changed, or hormonal therapy is initiated in a patient with prior mood instability. [3][7][17]" ], "subsections": [], "table": { "caption": "Escalation checkpoints in persistent PMDD symptoms. [4][14][16][17][20]", "columns": [ "Checkpoint", "Question to answer", "Action if abnormal" ], "rows": [ [ "Diagnostic confirmation", "Do ratings show luteal symptoms with postmenstrual remission for at least 2 symptomatic cycles? [14][16]", "Reclassify as PME or another disorder when symptoms remain clinically significant outside the luteal phase. [14][16]" ], [ "Psychiatric comorbidity", "Are depression, anxiety, bipolar-spectrum illness, or personality disorder contributing? [4][14]", "Treat the baseline disorder and involve psychiatry when indicated. [4][14][16]" ], [ "Failure of initial options", "Has an SSRI regimen and, when appropriate, a contraceptive strategy been adequately evaluated with daily ratings? [5][17]", "Consider specialist-directed ovulation suppression with a GnRH agonist for refractory confirmed PMDD. [2][8][20]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Help-seeking behaviours and experiences for mental health symptoms related to the menstrual cycle: a UK-wide exploratory survey | npj Women's Health", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s44294-023-00004-w", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 2, "title": "Premenstrual Syndrome and Dysphoric Disorder Management | Psychiatry | Clinical Sciences | Health sciences | Topics | Nature Index", "detail": "www.nature.com", "url": "https://www.nature.com/nature-index/topics/l4/premenstrual-syndrome-and-dysphoric-disorder-management", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 3, "title": "The impact of ovulation-suppressing contraceptives on behavioral and functional difficulties in borderline personality disorder | Neuropsychopharmacology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41386-024-02045-4", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 4, "title": "Premenstrual dysphoric disorder in online peer support communities: a Reddit case study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-025-19220-2", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 5, "title": "Evaluation and management of premenstrual dysphoric disorder ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/10.1097/MOP.0000000000001563", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 6, "title": "Premenstrual disorders including premenstrual... : The Obstetrician & Gynaecologist", "detail": "journals.lww.com", "url": "https://journals.lww.com/01034179-202325010-00008", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 7, "title": "Abstracts of Scientific Papers and Posters... : American Journal of Physical Medicine & Rehabilitation", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajpmr/fulltext/2016/03001/abstracts_of_scientific_papers_and_posters.1.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 8, "title": "[PDF] Guideline on the treatment of Premenstrual Dysphoric Disorder ...", "detail": "www.ema.europa.eu", "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf", "authors": "www.ema.europa.eu", "host": "www.ema.europa.eu" }, { "number": 9, "title": "London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP ...", "detail": "www.ema.europa.eu", "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf", "authors": "www.ema.europa.eu", "host": "www.ema.europa.eu" }, { "number": 10, "title": "Menstrual Disorders | AAP Books | American Academy of Pediatrics", "detail": "publications.aap.org", "url": "https://publications.aap.org/aapbooks/book/672/chapter/8113772/Menstrual-Disorders", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 11, "title": "Menstrual Disorders: Dysmenorrhea and Premenstrual ...", "detail": "publications.aap.org", "url": "https://publications.aap.org/book/chapter-pdf/795262/aap_9781581105650-part02-ch63.pdf", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 12, "title": "Navigating Unique Diagnostic and Therapeutic Challenges in Premenstrual Dysphoric Disorder: A Case Report - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11281859", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 13, "title": "Perimenstrual Exacerbation of Symptoms in Borderline Personality Disorder: Evidence from Multilevel Models and the Carolina Premenstrual Assessment Scoring System", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6436806", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 14, "title": "Diagnostic validity of premenstrual dysphoric disorder: revisited", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10711063", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 15, "title": "Making Strides to Simplify Diagnosis of Premenstrual Dysphoric Disorder - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5291290", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 16, "title": "Premenstrual Disorders - Abstract - Europe PMC", "detail": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/30335340", "authors": "pubmed.ncbi.nlm.nih.gov", "host": "pubmed.ncbi.nlm.nih.gov" }, { "number": 17, "title": "Premenstrual Disorders - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK532307", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 18, "title": "Table 1, Diagnostic Criteria for Premenstrual Dysphoric Disorder (PMDD) - Endotext - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK279045/table/premenstrual-syndrom.table1diag", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 19, "title": "Premenstrual dysphoric disorder: A review for the treating ...", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/content/ccjom/71/4/303.full.pdf", "authors": "www.ccjm.org", "host": "www.ccjm.org" }, { "number": 20, "title": "Women and headache: A treatment approach based on life ...", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/content/ccjom/69/6/488.full.pdf", "authors": "www.ccjm.org", "host": "www.ccjm.org" }, { "number": 21, "title": "Emotion Dysregulation of Women with Premenstrual Syndrome | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/srep38501", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 22, "title": "Differential grey matter structure in women with premenstrual dysphoric disorder: evidence from brain morphometry and data-driven classification | Translational Psychiatry", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41398-022-02017-6", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 23, "title": "Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator | Neuropsychopharmacology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41386-021-01010-9", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 24, "title": "Online positive-oriented counseling, taking vitamin D3 tablet, online lifestyle modification training on premenstrual syndrome: a 3-armed randomized clinical trial | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-023-43940-y", "authors": "www.nature.com", "host": "www.nature.com" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Help-seeking behaviours and experiences for mental health symptoms related to the menstrual cycle: a UK-wide exploratory survey | npj Women's Health", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s44294-023-00004-w", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Additionally, many individuals surveyed within the current study reported having looked online for treatment information. Effective treatments for PMS and PMDD are available21.\"), with current treatment recommendations including exercise, Selective Serotonin Uptake Inhibitors (SSRIs), combined oral ", "score": 0.60666215 }, { "number": 2, "title": "Premenstrual Syndrome and Dysphoric Disorder Management | Psychiatry | Clinical Sciences | Health sciences | Topics | Nature Index", "detail": "www.nature.com", "url": "https://www.nature.com/nature-index/topics/l4/premenstrual-syndrome-and-dysphoric-disorder-management", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD) are cyclical disorders of the menstrual cycle characterised by a constellation of physical, emotional and behavioural symptoms that emerge in the luteal phase and resolve with menstruation. While PMS affects up to half of menstru", "score": 0.5654673 }, { "number": 3, "title": "The impact of ovulation-suppressing contraceptives on behavioral and functional difficulties in borderline personality disorder | Neuropsychopharmacology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41386-024-02045-4", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "containing drospirenone, in managing premenstrual dysphoric disorder (PMDD) . These studies suggest that the effects of hormonal contraceptives are not uniform and may depend on individual sensitivities to different formulations and schedules. Thus, while hormonal contraceptives may exacerbate sympt", "score": 0.4450718 }, { "number": 4, "title": "Premenstrual dysphoric disorder in online peer support communities: a Reddit case study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-025-19220-2", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \nADS \nGoogle Scholar\n\nKleinstäuber, M., Witthöft, M. & Hiller, W. Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis. J. Clin. Psychol. Med. Settings 19, 308–319 (2012).\n\nArticle \nPubMed \nGoogle Scholar\n\nSepede", "score": 0.4189114 }, { "number": 5, "title": "Evaluation and management of premenstrual dysphoric disorder ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/10.1097/MOP.0000000000001563", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "This review summarizes current evidence on how to evaluate and treat premenstrual dysphoric disorder (PMDD) in pediatric patients. It highlights that PMDD can be hard to diagnose, leading to delays in care, and that these challenges can be greater for youth with comorbid mental health disorders and ", "score": 0.54753727 }, { "number": 6, "title": "Premenstrual disorders including premenstrual... : The Obstetrician & Gynaecologist", "detail": "journals.lww.com", "url": "https://journals.lww.com/01034179-202325010-00008", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Advertisement\n\nOvid® Ovid Logo\n\nSearch Ovid Search Ovid\n\nBrowse Browse\n\nLogin Login\n\nThe Obstetrician & Gynaecologist\n\nNavbar\n\nMenu\n\n Current Issue \n Previous Issues \n Latest Articles \n\n More menu items \n\nSearch Journal Search Journal\n\nButton group.\n\n Check Access \n Image 1Permissi", "score": 0.35213548 }, { "number": 7, "title": "Abstracts of Scientific Papers and Posters... : American Journal of Physical Medicine & Rehabilitation", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajpmr/fulltext/2016/03001/abstracts_of_scientific_papers_and_posters.1.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Case Description: The patient is a 17 year old previously healthy female involved in a motor vehicle collision, sustaining severe traumatic brain injury (TBI), basilar and temporal skull fractures, and subarachnoid hemorrhage. Her inpatient rehabilitation course was uneventful; however, nine months ", "score": 0.28522807 }, { "number": 8, "title": "[PDF] Guideline on the treatment of Premenstrual Dysphoric Disorder ...", "detail": "www.ema.europa.eu", "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf", "authors": "www.ema.europa.eu", "host": "www.ema.europa.eu", "snippet": "theories regarding the underlying causes of PMDD, two main treatment options have been developed: (1) targeting the hypothalamus-pituitary-ovary axis by abolishing fluctuations in gonadal hormone levels (e.g. GnRH analogues, oestradiol, combined oral contraceptives (COCs)) and (2) targeting brain se", "score": 0.6864757 }, { "number": 9, "title": "London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP ...", "detail": "www.ema.europa.eu", "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf", "authors": "www.ema.europa.eu", "host": "www.ema.europa.eu", "snippet": "guidelines for their quantification for research studies. Gynecol Endocrinol 23, 123-30 (2007). 8. Inoue, Y. et al. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology (Berl) 190, 213-9 (2007", "score": 0.50183165 }, { "number": 10, "title": "Menstrual Disorders | AAP Books | American Academy of Pediatrics", "detail": "publications.aap.org", "url": "https://publications.aap.org/aapbooks/book/672/chapter/8113772/Menstrual-Disorders", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "Fluoxetine, sertraline, and paroxetine are the only US Food and Drug Administration–approved SSRIs for use in the management of severe PMS/PMDD. Although", "score": 0.33313483 }, { "number": 11, "title": "Menstrual Disorders: Dysmenorrhea and Premenstrual ...", "detail": "publications.aap.org", "url": "https://publications.aap.org/book/chapter-pdf/795262/aap_9781581105650-part02-ch63.pdf", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "studied combined hormonal contraceptive treatment for dysmenorrhea is the oral contraceptive pill (OCP), which works indirectly by inhibiting ovulation and.", "score": 0.24457085 }, { "number": 12, "title": "Navigating Unique Diagnostic and Therapeutic Challenges in Premenstrual Dysphoric Disorder: A Case Report - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11281859", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Our patient fulfilled the PMDD criteria of having at least 5 out of 11 stipulated symptoms identified in the DSM-5, one of which must include mood, behavioral, or physical symptoms with substantial stress or functional impairment. Confirming symptoms by prospective patient mood charting for at least", "score": 0.82492816 }, { "number": 13, "title": "Perimenstrual Exacerbation of Symptoms in Borderline Personality Disorder: Evidence from Multilevel Models and the Carolina Premenstrual Assessment Scoring System", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6436806", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Given overlapping risk factors and core symptom content in PMDD and BPD, we predicted a majority (>50%) of the sample would meet the C-PASS diagnostic criterion of _premenstrual elevation_ (>= 30% higher premenstrually vs. postmenstrually) on at least one emotional symptom. Results of individual C-P", "score": 0.7961819 }, { "number": 14, "title": "Diagnostic validity of premenstrual dysphoric disorder: revisited", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10711063", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "The screening tools for premenstrual symptoms, including both adult and adolescent versions, are widely used in clinical practice (21, 22). The structured clinical interview for DSM-IV-TR PMDD (SCID-PMDD) is a diagnostic interview schedule developed in 2013 (23), which includes five scales (24–28) f", "score": 0.7636429 }, { "number": 15, "title": "Making Strides to Simplify Diagnosis of Premenstrual Dysphoric Disorder - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5291290", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "In the clinical setting, the process of making a diagnosis of PMDD is unlike that of any other affective disorder. Prospective daily ratings are required because retrospective reporting of symptoms has poor consistency with prospectively confirmed PMDD or expert clinician diagnosis (1, 9). However, ", "score": 0.7474137 }, { "number": 16, "title": "Premenstrual Disorders - Abstract - Europe PMC", "detail": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/30335340", "authors": "pubmed.ncbi.nlm.nih.gov", "host": "pubmed.ncbi.nlm.nih.gov", "snippet": "Disorders. Diagnosis of PMDD requires fulfillment of specific criteria during the majority of menstrual cycles over the preceding year.The following components comprise the criteria that must be met to diagnose PMDD: Criterion A (timing): Symptoms must occur during the final week before the onset of", "score": 0.68723184 }, { "number": 17, "title": "Premenstrual Disorders - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK532307", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "## Evaluation\n\nSeveral validated assessment instruments support the diagnosis, symptom monitoring, and severity assessment of PMDD. These tools facilitate standardized symptom documentation, improve diagnostic accuracy, and assist clinicians in monitoring treatment response over time.\n\nDaily Record ", "score": 0.68064564 }, { "number": 18, "title": "Table 1, Diagnostic Criteria for Premenstrual Dysphoric Disorder (PMDD) - Endotext - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK279045/table/premenstrual-syndrom.table1diag", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "| Confirmation of the disorder F) Criterion A should be confirmed by prospective daily ratings during at least 2 symptomatic cycles (although a provisional diagnosis may be made prior to this confirmation)Exclude other Medical Explanations G) The symptoms are not attributable to the physiological", "score": 0.6172364 }, { "number": 19, "title": "Premenstrual dysphoric disorder: A review for the treating ...", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/content/ccjom/71/4/303.full.pdf", "authors": "www.ccjm.org", "host": "www.ccjm.org", "snippet": "Selective serotonin reuptake inhibitors (SSRIs)45–58 are the first-line drugs for PMDD and have been shown to be effective in more than 60% of treated patients.45,46 Treatment only during the luteal phase (10–14 days before menses begins) works as well as full-cycle dosing, with fewer adverse effect", "score": 0.44391435 }, { "number": 20, "title": "Women and headache: A treatment approach based on life ...", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/content/ccjom/69/6/488.full.pdf", "authors": "www.ccjm.org", "host": "www.ccjm.org", "snippet": "Alternatively, PMDD symptoms may be triggered by hormonal events that occur before the late luteal phase, a theory consis-tent with reports that suppression of ovulation with gonadotropin-releasing hormone usually decreases PMDD symptoms.62–65 When headache and PMDD occur in the same patient, an SSR", "score": 0.3713423 }, { "number": 21, "title": "Emotion Dysregulation of Women with Premenstrual Syndrome | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/srep38501", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "related to the impacts of the menstrual cycle on women’s emotional changes have been primarily conducted among patients who suffer from premenstrual syndrome (PMS) and its severe predominantly psychological form: premenstrual dysphoric disorder (PMDD)2, 555–568 (2005).\"). PMS is defined as a group o", "score": 0.4172008 }, { "number": 22, "title": "Differential grey matter structure in women with premenstrual dysphoric disorder: evidence from brain morphometry and data-driven classification | Translational Psychiatry", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41398-022-02017-6", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Premenstrual dysphoric disorder (PMDD) is recognized in the DSM-5 as a hormone-related depressive disorder, specific to women’s mental health [1; 2013.\")]. Women who suffer from PMDD experience affective, cognitive, and physical symptoms that peak during the late luteal phase of the menstrual cycle,", "score": 0.32849765 }, { "number": 23, "title": "Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator | Neuropsychopharmacology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41386-021-01010-9", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "### Explore related subjects\n\n## Introduction\n\nPremenstrual dysphoric disorder (PMDD) is a mood disorder characterized by affective symptoms, such as irritability and anger, and more frequent reports of interpersonal conflicts [1][2]. Diminished emotional regulation due to impaired impulse control i", "score": 0.3265296 }, { "number": 24, "title": "Online positive-oriented counseling, taking vitamin D3 tablet, online lifestyle modification training on premenstrual syndrome: a 3-armed randomized clinical trial | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-023-43940-y", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \nPubMed \nGoogle Scholar\n\nMaskani, S., Tafazoli, M., Rakhshandeh, H. & Esmaily, H. Effect of Nigella sativa seeds on the severity of symptoms of premenstrual syndrome: A randomized clinical trial. Koomesh J. 22, 33–40. (2020).\n\nArticle \nGoogle Scholar\n\nCerqueira, R. O., Frey, B. N., Leclerc,", "score": 0.32540315 } ], "publishedAt": "2026-09-15T17:23:47.835472+00:00", "updatedAt": "2026-09-15T17:23:47.835472+00:00", "readingMinutes": 7, "slug": "premenstrual-dysphoric-disorder" }